Certolizumab Pegol FDA Link

A polyethylene-glycolated Fab' fragment of TUMOR NECROSIS FACTOR antibody that binds specifically to TNF-ALPHA and neutralises it in a dose-dependent manner. It also inhibits the production of lipopolysaccharide-induced TNF-ALPHA and IL-1 BETA and is used to treat RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.

Also Known As:

CDP 870; CDP870; Cimzia

Macromolecular Substances: 97
- Polymers: 13529
  - Polyethylene Glycols: 3955
    - Certolizumab Pegol: 546
Amino Acids, Peptides, and Proteins: 1
- Proteins: 496323
  - Blood Proteins: 12679
    - Serum Globulins: 555
      - Immunoglobulins: 30911
        Antibodies: 135587
        Monoclonal Antibodies: 57170
        Humanized Monoclonal Antibodies: 220
        Certolizumab Pegol: 546
        Immunoglobulin Fragments: 979
        Immunoglobulin Fab Fragments: 766
        Certolizumab Pegol: 546
    - Immunoproteins: 43
      - Immunoglobulins: 30911
        Antibodies: 135587
        Monoclonal Antibodies: 57170
        Humanized Monoclonal Antibodies: 220
        Certolizumab Pegol: 546
        Immunoglobulin Fragments: 979
        Immunoglobulin Fab Fragments: 766
        Certolizumab Pegol: 546
  - Globulins: 3119
    - Serum Globulins: 555
      - Immunoglobulins: 30911
        Antibodies: 135587
        Monoclonal Antibodies: 57170
        Humanized Monoclonal Antibodies: 220
        Certolizumab Pegol: 546
        Immunoglobulin Fragments: 979
        Immunoglobulin Fab Fragments: 766
        Certolizumab Pegol: 546
- Peptides: 84029
  - Peptide Fragments: 379
    - Immunoglobulin Fragments: 979
      - Immunoglobulin Fab Fragments: 766
        Certolizumab Pegol: 546

Corinne Jamoul Selected Research

Corinne Jamoul Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure